Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2015-04-15

Clinical Trial Update: A Safety and Efficacy Study of Fabrazyme® Replacement Therapy in Patients With Cardiac Fabry Disease [Phase 4]

View source ↗

Summary

Phase 4 study evaluating the safety and efficacy of Fabrazyme replacement therapy in patients with cardiac Fabry disease. Results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • FABRAZYME (Agalsidase beta)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Fabry Disease | Phase 4 | Status: COMPLETED | Results posted: 2015-04-15